前列腺癌根治性或术后放疗后复发再程放疗的国际注册研究
中位随访54个月,无治疗相关死亡,急性GU和GI毒性未报告率分别为64.2%和90.3%,晚期G2和G3 GU毒性分别为16.2%和4.8%,生化复发239例(55.2%)。结论认为再程放疗安全、可行且有效。
要点
- 再程放疗未出现治疗相关死亡,急性GU和GI毒性未报告率分别为64.2%和90.3%。
- 晚期G2和G3 GU毒性分别为16.2%和4.8%,安全性可接受。
- 中位随访54个月,生化复发239例(55.2%),区域或远处复发119例(27.2%),死亡95例(21.9%)。
核心结论
- 结果证实前列腺癌再程放疗安全、可行且有效,并提示与肿瘤学结局改善相关的特征。
研究设计与样本
- RESTART为观察性纵向研究,纳入既往根治性或术后放疗后按EAU标准生化复发、PET-CT或MRI可见前列腺或瘤床宏观复发的患者。
- 患者接受SBRT或近距离治疗,EBRT分次剂量至少5 Gy,对分次方案或总剂量无其他限制。
主要发现
- 64.2%和90.3%的患者未报告任何急性GU或GI毒性,未登记治疗相关死亡。
- 晚期G2和G3 GU毒性分别见于16.2%和4.8%的患者。
- 中位随访54个月(95%CI 26-78),记录生化复发239例(55.2%)、影像确认的区域或远处复发119例(27.2%)、死亡95例(21.9%)。
临床怎么用
- 对根治性或术后放疗后前列腺或瘤床宏观复发且无区域淋巴结或远处转移的患者,可考虑SBRT或近距离再程放疗。
- 再程放疗前需排除既往放疗持续严重毒性,并确保随访至少6个月以评估安全性。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aiming to evaluate the long-term safety of re-irradiation approaches, the Italian Association for Radiotherapy and Clinical Oncology Oncology (AIRO) re-irradiation study group proposed the institution of a multicentric registry including prostate cancer patients undergoing re-irradiation for local relapse after postoperative or definitive RT. MATERIALS AND METHODS: RESTART is an observational longitudinal study including patients with biochemical relapse according to EAU criteria after a previous course of definitive or postoperative RT, and treated for a macroscopic recurrence within the prostate or prostate bed visualized on PET-CT or magnetic resonance imaging (MRI). Patients were treated with stereotactic body radiotherapy (SBRT) or brachytherapy (BT), with fraction doses of at least 5 Gy for EBRT, and no other restrictions regarding fractionation schedule or total dose. Exclusion criteria consisted of the presence of regional nodal disease or distant metastases, persisting severe toxicities from previous RT or follow-up shorter than 6 months. RESULTS: Four hundred and thirty-three patients from 5 centers were included in the current analysis. Overall, 64.2 % and 90.3 % of patients did not report any acuteGU or GI toxicity. No treatment-related deaths were registered. LateG2 or G3 GU toxicity was reported in 16.2 and 4.8 % of patients, respectively. After a median follow-up of 54 months (95 % CI 26-78), 239 biochemical recurrences (55.2 %), 119 radiologically-confirmed regional or distant relapses (27.2 %), and 95 deaths (21.9 %) were recorded, respectively. CONCLUSION: Results confirm the safety, feasibility, and efficacy of re-irradiation for prostate cancer, and provide insights about features associated with improved oncological outcomes after treatment.
引用
- Francolini G, Cataldo VD, Caini S, et al. Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START). Radiother Oncol. 2025. PMID: 40953707. doi:10.1016/j.radonc.2025.111138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。